Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis

Ryu WatanabeDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Tomonori IshiiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, JapanCorrespondence[email protected]

Kyoko ArakiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Mariko IshizukaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Yukiko KamogawaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Yoko FujitaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Yuko ShirotaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Hiroshi FujiiDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Hideo HarigaeDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan

show all

"Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis." Modern Rheumatology, 26(3), pp. 465–466

Acknowledgment

We would like to thank Dr. Manabu Fujimoto, the Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Japan, for the measurement of anti-MDA5 antibody. The treatment protocol was approved by the Ethical Committee of Tohoku University Graduate School of Medicine.

Conflict of interest

None.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis

Information for

Open access

Opportunities

Help and information

Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis

Acknowledgment

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature